clinical trial · NCT06643884
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Eye CancerPrimary CancerAU-011SCS MicroinjectorLaser
brief summary
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
started
Dec 16, 2024
primary completion
Nov 30, 2026
completion
Oct 31, 2027
last updated
Mar 13, 2026
detailed description
This is an open-label, dose escalation trial designed to assess safety and tolerability of 4 dose strengths and 1-2 cycles of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
official title
A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Belzupacap Sarotalocan (AU-011) With Suprachoroidal Administration in Subjects With Metastases to the Choroid
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol